Story
Alligator Bioscience Stock Plummets Over 73% After Halting Lead Cancer Drug Program
Summary
Shares of the Swedish biotech firm collapsed after it announced it would discontinue in-house development of its pancreatic cancer drug, mitazalimab, and seek a rights issue to secure funding.
Shares in Alligator Bioscience plummeted on Thursday after the Swedish biotechnology company announced it would halt the independent development of its lead drug candidate, mitazalimab, and launch a rights issue to strengthen its financial position.
Strategic Shift and Financial Measures
Alligator Bioscience said the decision follows a reassessment of the pancreatic cancer market, where recent advances in targeted therapies are altering the competitive landscape. The company now intends to out-license or divest mitazalimab and will refocus its efforts on its HLX22 project.
To shore up its finances, Alligator announced a series of measures, including:
- A proposed SEK 125.6 million rights issue, subject to shareholder approval.
- Undertakings and guarantees covering SEK 58.8 million, or 47% of the rights issue.
- Bridge loan agreements totaling SEK 19 million to secure near-term liquidity.
The company also stated it plans to wind down other activities and reduce its organizational size to minimize operating costs.
AdMarket Reaction
The market's response was severe. Alligator Bioscience's stock crashed 73.6% to SEK 0.0513 by 07:56 GMT, according to Investing.com. The dramatic sell-off reduced the company's market capitalization to just SEK 32.5 million.
Company Rationale
CEO Soren Bregenholt called the move a "very difficult but necessary decision." He explained that while the company believes mitazalimab has potential, the rapidly changing treatment landscape has made in-house development no longer commercially viable.
"In addition, we need to recognize that the resources required to reposition the program are not available to Alligator Bioscience," Bregenholt said in a statement. This pivot signals a significant strategic retreat from what was previously the company's flagship program.
Read next
More on Stocks
Indian Insurance Stocks Plunge on Proposed Overhaul of Commission Rules
Shares of Indian insurance and fintech companies fell sharply after the country's regulator proposed a significant overhaul of commission structures, which could cap payouts to agents and distributors.
Capricorn Energy Lifts Output Forecast Amid Competing Takeover Bids
Capricorn Energy raised its full-year production forecast, citing strong performance from its Egyptian assets, as it continues to evaluate competing takeover offers from DNO and Genel Energy.
Honda Plans Up to $2.5 Billion Hybrid Vehicle Plant in Ohio, Nikkei Reports
The Japanese automaker is reportedly in the final stages of planning a new facility with an investment of up to ¥400 billion ($2.53 billion) to meet rising consumer demand for hybrid models in North America.
JPMorgan Appoints Francesco Lavatelli to Lead Japan Operations
JPMorgan has named Francesco Lavatelli as its new senior country officer for Japan, effective Dec. 1, as part of a leadership shuffle that sees former head Steve Rinoie move into a global role.